Eovist FDA Approval History
FDA Approved: Yes (First approved July 3, 2008)
Brand name: Eovist
Generic name: gadoxetate disodium
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Diagnosis and Investigation
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.
Development Timeline for Eovist
|Jul 8, 2008||ApprovalFDA Approves Eovist to Detect and Characterize Focal Liver Lesions|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.